Source: Pharmacy Times articles
Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.
Recent Content
- High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma
- Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials
- Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
- You Are Not Alone While Building a Support Team During Cancer Care
- Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma
- When Treatment Ends, Support Shouldn’t Stop in Cancer Care
- Sequencing Strategies and the Role of Combination Therapy
- Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
- Being in the Present Moment With Multiple Myeloma
- Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis